drugset / Trial / NCT05884281

Efficacy of Roflumilast in Prevention of Peripheral Neuropathy

NCT05884281

Phase 1/2 Unknown 60 enrolled Mansoura University
RandomizedParallel-groupDouble-blindPrevention

Summary

There are several mechanisms concerning pathophysiology of paclitaxel induced peripheral neuropathy. One of the main mechanisms is induction of Schwann cell dedifferentiation by paclitaxel. At the preclinical level, roflumilast potently inhibited paclitaxel-induced dedifferentiation of cultured Schwann cells, yet this positive effect have not been clinically investigated.

Timeline

Start
2023-07
Primary completion
2023-12
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Roflumilast Small molecule 0.5 mg

Indications